Efficacy Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice

机译：法国临床实践雷戈非尼治疗转移性结直肠癌的疗效安全性和费用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUNDRegorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved survival in two international phase 3 trials (CORRECT and CONCUR), a high rate of treatment-related toxic effects and dose modifications were observed with a modest benefit. The aim of this study was to provide information concerning the efficacy, safety, and cost of regorafenib in patients with mCRC in clinical practice.

机译：背景Regorafenib是一种口服多激酶抑制剂，已被批准用于化疗难治性转移性结直肠癌（mCRC）患者。尽管瑞格非尼在两项国际3期试验（CORRECT和CONCUR）中显着提高了生存率，但仍观察到较高的治疗相关毒性作用和剂量调整，但获益不大。这项研究的目的是提供有关瑞戈非尼在临床实践中对mCRC患者的疗效，安全性和费用的信息。

著录项

期刊名称 Clinical Medicine Insights. Oncology
作者
Fabien Calcagno; Sabrina Lenoble; Zaher Lakkis; Thierry Nguyen; Samuel Limat; Christophe Borg; Marine Jary; Stefano Kim; Virginie Nerich;
展开▼
作者单位

展开▼
年(卷),期 2016(10),-1
年度 2016
页码 59–66
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
metastatic colorectal cancer regorafenib cost efficacy safety;

机译：转移性结直肠癌;瑞格非尼;成本;疗效;安全性;
入库时间 2022-08-17 13:07:15

相似文献

外文文献
中文文献
专利

1. Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice [J] . Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Clinical Medicine Insights: Oncology . 2016,第9期

机译：法国临床实践雷戈非尼治疗转移性结直肠癌的疗效，安全性和费用
2. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study [J] . Ducreux Michel, Petersen Lone Norgard, Oehler Leopold, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：常规临床实践中术治疗前瞻性，观测相关研究的术语患者的安全性和有效性
3. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution [J] . Kotani Daisuke, Shitara Kohei, Kawazoe Akihito, Clinical colorectal cancer . 2016,第3期

机译：三氟哌啶/替吡拉西单药治疗转移性结直肠癌患者的安全性和有效性：在一个机构中的经验
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. A Modeling-Based Evaluation of the Evidential Basis for and Cost Effectiveness of Intensive Post-Diagnosis Extra-Colonic Surveillance of Non-Metastatic Colorectal Cancer Patients [D] . Popp, Jonah. 2018

机译：非转移性结直肠癌患者强化诊断后大肠结肠镜检查的证据基础和成本效益的基于模型的评估
6. P-277A prospective observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE) [O] . Ducreux Michel, Falcone Alfredo, Cornelis J.A. Punt, -1

机译：P-277A一项前瞻性观察性试验旨在评估雷戈非尼在常规临床实践中对转移性结直肠癌（mCRC）患者的安全性和有效性（CORRELATE）
7. P-277 A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE) [O] . Ducreux Michel, Falcone Alfredo, Cornelis J.A. Punt, 2016

机译：P-277常规，观测试验，以评估常规临床实践中转移性结肠直肠癌（MCRC）患者中雷罗妥昔韦的安全性和功效（相关）

Efficacy Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice

摘要

著录项

相似文献

相关主题

期刊订阅